Cryo-Cell was recently invited to attend a conference held in New York City sponsored by the Alliance for Regenerative Medicine. This conference brought together leading regenerative medicine and advanced cellular therapy companies to share plans for and results from clinical trials that mainly use stem cell-based therapies to treat numerous diseases, ranging from oncology and cardiovascular to neurologic. Although stem cell scientists from all over the world attended, Cryo-Cell had the distinct honor of representing the cord blood banking industry.
Cryo-Cell was asked to participate due to its leadership role in advancing the use of cord blood, through its research affiliate, Saneron-CCEL Therapeutics, to treat neurological degenerative diseases, such as Alzheimer’s, Parkinson’s and Lou Gehrig's disease. Saneron-CCEL’s scientists are internationally recognized for their cord blood expertise to the extent that several of the regenerative medicine companies presenting at the conference have contracted with Saneron to assist them in preclinical studies of stem and progenitor cells. In comparison to the stem cells used in many of the trials that were described at the conference, cord blood and cord tissue stem cells exhibit distinct advantages. These advantages include being less subjected to environmental exposure that leads to mutations, immediate availability for treatment to minimize disease progression, less risk of graft versus host disease when used in transplants due to the cells being more immunologically naive, and more.
Last Updated on: 10/28/2016 by Oleg Mikulinsky